Research graph
References from CAR T-cells for the treatment of CNS malignancies. Local targets link to admitted publications; unresolved targets remain external evidence.
Expression of chimeric receptor composed of immunoglobulin-derived V resions and T-cell receptor-derived C regions
10.1016/0006-291x(87)90502-x · 1987 · External reference
Frontiers | From bench to bedside: the history and progress of CAR T cell therapy
10.3389/fimmu.2023.1188049 · 2023 · External reference
Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity
10.1073/pnas.86.24.10024 · 1989 · External reference
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors
10.1073/pnas.90.2.720 · 1993 · External reference
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification - PubMed
10.1200/jco.2013.54.8800 · 2014 · External reference
Circulating tumor dna as measurable residual disease in aggressive b-cell lymphoma
10.1001/jamaoncol.2024.6144 · 2025 · External reference
Axicabtagene Ciloleucel CAR T-Cell therapy in refractory large b-cell lymphoma
10.1056/nejmoa1707447 · 2017 · External reference
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
10.1016/s0140-6736(20)31366-0 · 2020 · External reference
Tisagenlecleucel in adult relapsed or refractory diffuse large b-cell lymphoma
10.1056/nejmoa1804980 · 2019 · External reference
KTE-X19 CAR T-Cell therapy in relapsed or refractory mantle-cell lymphoma
10.1056/nejmoa1914347 · 2020 · External reference
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
10.1038/s41591-021-01622-0 · 2022 · External reference
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
10.1016/s1470-2045(21)00591-x · 2022 · External reference
Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia
10.1056/nejmoa1709866 · 2018 · External reference
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
10.1016/s0140-6736(21)01222-8 · 2021 · External reference
Cytokine release syndrome with chimeric antigen receptor t cell therapy
10.1016/j.bbmt.2018.12.756 · 2019 · External reference
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy
10.1182/blood-2017-06-793141 · 2017 · External reference
ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells
10.1016/j.bbmt.2018.12.758 · 2019 · External reference
Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
10.1038/nrclinonc.2017.148 · 2017 · External reference
Tumor inflammation-associated neurotoxicity
10.1038/s41591-023-02276-w · 2023 · External reference
Toxicity and management in CAR T-cell therapy
10.1038/mto.2016.11 · 2016 · External reference
Efficiency of CAR‐T therapy for treatment of solid tumor in clinical trials: a meta‐analysis
10.1155/2019/3425291 · 2019 · External reference
Time to abandon CAR-T monotherapy for solid tumors
10.1016/j.bbcan.2023.188930 · 2023 · External reference
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
10.1038/s41571-023-00832-4 · 2023 · External reference
CAR-T cell therapy: current limitations and potential strategies
10.1038/s41408-021-00459-7 · 2021 · External reference
Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors
10.1186/s12935-024-03315-3 · 2024 · External reference
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment
10.1186/s40164-023-00373-7 · 2023 · External reference
CAR‐T‐cell products in solid tumors: Progress, challenges, and strategies
10.1002/inmd.20230047 · 2024 · External reference
Adoptive cell therapy for cancer treatment
10.1002/exp.20210058 · 2023 · External reference
CAR-T design: Elements and their synergistic function
10.1016/j.ebiom.2020.102931 · 2020 · External reference
T Cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase t cell activation against antigen-positive target cells but decreases selectivity
10.4049/jimmunol.173.12.7647 · 2004 · External reference
Affinity-Tuned ErbB2 or EGFR chimeric antigen receptor t cells exhibit an increased therapeutic index against tumors in mice
10.1158/0008-5472.can-15-0159 · 2015 · External reference
Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells
10.1158/1078-0432.ccr-13-0330 · 2013 · External reference
A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization
10.1016/j.ymthe.2017.04.024 · 2017 · External reference
A safe and potent anti-CD19 CAR T cell therapy
10.1038/s41591-019-0421-7 · 2019 · External reference
CAR T cells for brain tumors: Lessons learned and road ahead
10.1111/imr.12773 · 2019 · External reference
Challenges and new technologies in adoptive cell therapy
10.1186/s13045-023-01492-8 · 2023 · External reference
Alternative target recognition elements for chimeric antigen receptor (CAR) T cells: beyond standard antibody fragments
10.1016/j.jcyt.2024.02.024 · 2024 · External reference
Current updates on generations, approvals, and clinical trials of CAR T-cell therapy
10.1080/21645515.2022.2114254 · 2022 · External reference
Chimeric antigen receptor T cell structure, its manufacturing, and related toxicities; A comprehensive review
10.1016/j.adcanc.2022.100035 · 2022 · External reference
Secretory protein trafficking and organelle dynamics in living cells
10.1146/annurev.cellbio.16.1.557 · 2000 · External reference
Hinge and transmembrane domains of chimeric antigen receptor regulate receptor expression and signaling threshold
10.3390/cells9051182 · 2020 · External reference
Regulation of T cell receptor activation by dynamic membrane binding of the CD3epsilon cytoplasmic tyrosine-based motif
10.1016/j.cell.2008.09.044 · 2008 · External reference
The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity
10.1158/2326-6066.cir-14-0127 · 2015 · External reference
Designing chimeric antigen receptors to effectively and safely target tumors
10.1016/j.coi.2015.01.002 · 2015 · External reference
Tuning the antigen density requirement for car t-cell activity
10.1158/2159-8290.cd-19-0945 · 2020 · External reference
Function of novel Anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains
10.1016/j.ymthe.2017.07.013 · 2017 · External reference
Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model
10.1038/gt.2015.4 · 2015 · External reference
Cells expressing CD19/CD20 Bispecific chimeric antigen receptors prevent antigen escape by Malignant B cells
10.1158/2326-6066.cir-15-0231 · 2016 · External reference
Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells
10.1007/s00262-019-02376-y · 2019 · External reference
A novel CD34-derived hinge for rapid and efficient detection and enrichment of CAR T cells
10.1016/j.omto.2021.11.003 · 2021 · External reference
Extracellular NGFR spacers allow efficient tracking and enrichment of fully functional car-t cells co-expressing a suicide gene
10.3389/fimmu.2018.00507 · 2018 · External reference
Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response
10.1038/gt.2010.91 · 2010 · External reference
Recent advances on CAR-T signaling pave the way for prolonged persistence and new modalities in clinic
10.3389/fimmu.2024.1335424 · 2024 · External reference
CAR-T cell potency: from structural elements to vector backbone components
10.1186/s40364-022-00417-w · 2022 · External reference
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
10.1172/jci.insight.96976 · 2018 · External reference
Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors
10.1038/s43018-021-00244-2 · 2021 · External reference
Trogocytosis of chimeric antigen receptors between T cells is regulated by their transmembrane domains
10.1126/sciimmunol.ado2054 · 2025 · External reference
Engineering CAR-T cells
10.1186/s40364-017-0102-y · 2017 · External reference
CAR T cells: engineered immune cells to treat brain cancers and beyond
10.1186/s12943-022-01712-8 · 2023 · External reference
CARs: Beyond T cells and T cell-derived signaling domains
10.3390/ijms21103525 · 2020 · External reference
The organizing principle in the formation of the T cell receptor-CD3 complex
10.1016/s0092-8674(02)01194-7 · 2002 · External reference
Non-catalytic tyrosine-phosphorylated receptors
10.1111/imr.12008 · 2012 · External reference
The expanding role for ITAM-based signaling pathways in immune cells
10.1126/stke.3772007re2 · 2007 · External reference
From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy
10.1177/1535370215584936 · 2015 · External reference
Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary t lymphocytes
10.1084/jem.188.4.619 · 1998 · External reference
CD28 co-stimulus achieves superior CAR T cell effector function against solid tumors than 4-1BB co-stimulus
10.3390/cancers13051050 · 2021 · External reference
Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations
10.1002/cti2.1049 · 2019 · External reference
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
10.1038/s41571-021-00530-z · 2021 · External reference
Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells
10.1016/j.immuni.2016.01.021 · 2016 · External reference
Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors
10.3324/haematol.2010.026310 · 2010 · External reference
Engineering T cell function using chimeric antigen receptors identified using a dna library approach
10.1371/journal.pone.0063037 · 2013 · External reference
In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-hodgkin’s lymphomas
10.1016/j.ymthe.2018.09.009 · 2018 · External reference
Third-Generation CAR T cells targeting CD19 are associated with an excellent safety profile and might improve persistence of car t cells in treated patients
10.1182/blood-2019-125423 · 2019 · External reference
Functional tuning of CARs reveals signaling threshold above which CD8+ CTL antitumor potency is attenuated due to cell FAS–FASL-dependent AICD
10.1158/2326-6066.cir-14-0200 · 2015 · External reference
Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28–OX40 “Super-stimulation
10.1038/mt.2013.192 · 2013 · External reference
A Phase I/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia
10.1158/1078-0432.ccr-18-0426 · 2018 · External reference
CAR T Cells releasing IL-18 convert to t-bethigh foxo1low effectors that exhibit augmented activity against advanced solid tumors
10.1016/j.celrep.2017.11.063 · 2017 · External reference
Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18
10.1016/j.celrep.2017.09.002 · 2017 · External reference
IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
10.1038/nbt.4086 · 2018 · External reference
Synthetic cytokine circuits that drive T cells into immune-excluded tumors
10.1126/science.aba1624 · 2022 · External reference
Multidimensional control of therapeutic human cell function with synthetic gene circuits
10.1126/science.ade0156 · 2022 · External reference
IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell–mediated rejection of systemic lymphoma in immunodeficient mice
10.1182/blood-2009-09-241398 · 2010 · External reference
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety
10.1038/leu.2010.75 · 2010 · External reference
Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer
10.1136/jitc-2021-003897 · 2022 · External reference
GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma
10.1136/jitc-2022-005187 · 2022 · External reference
Eradication of neuroblastoma by T Cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15
10.1158/1078-0432.ccr-18-1811 · 2019 · External reference
Inducible secretion of IL-21 augments anti-tumor activity of piggyBac-manufactured chimeric antigen receptor T cells
10.1016/j.jcyt.2020.08.005 · 2020 · External reference
IL-23 and PSMA-targeted duo-CAR T cells in prostate cancer eradication in a preclinical model
10.1186/s12967-019-02206-w · 2020 · External reference
Interleukin-23 engineering improves CAR T cell function in solid tumors
10.1038/s41587-019-0398-2 · 2020 · External reference
Reversal of tumor immune inhibition using a chimeric cytokine receptor
10.1038/mt.2014.47 · 2014 · External reference
Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4
10.1074/jbc.m110.127951 · 2010 · External reference
A chimeric GM-CSF/IL18 receptor to sustain CAR T-cell function
10.1158/2159-8290.cd-20-0896 · 2021 · External reference
CD28-ζ CAR T Cells Resist TGF-β repression through IL-2 Signaling, which can be mimicked by an engineered IL-7 autocrine loop
10.1016/j.ymthe.2018.07.005 · 2018 · External reference
Systematic review of available CAR-T cell trials around the world
10.3390/cancers14112667 · 2022 · External reference
A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects
10.1038/nm.4478 · 2018 · External reference
Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition
10.1016/j.intimp.2022.109442 · 2022 · External reference
Overview of metastatic disease of the central nervous system
10.1016/b978-0-12-811161-1.00001-3 · 2018 · External reference
CSF tumor dna genotyping and survival among patients with cns metastases
10.1001/jamanetworkopen.2020.9077 · 2020 · External reference
Brain metastasis in de novo stage IV breast cancer
10.1016/j.breast.2023.07.005 · 2023 · External reference
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort
10.1038/s41416-019-0619-y · 2019 · External reference
Five-year survival among patients with advanced skin, renal, and lung cancer treated with Nivolumab
10.1001/jamaoncol.2019.2187 · 2019 · External reference
Survival improvements in patients with melanoma brain metastases and leptomeningeal disease in the modern era: Insights from a nationwide study (2015–2022)
10.1016/j.ejca.2025.115253 · 2025 · External reference
Clinical characteristics and treatment outcomes of patients with colorectal cancer who develop brain metastasis: a single institution experience
10.21037/jgo.2016.12.11 · 2017 · External reference
Overall survival and response to radiation and targeted therapies among patients with renal cell carcinoma brain metastases
10.3171/2018.8.jns182100 · 2019 · External reference
Brain metastases: epidemiology and pathophysiology
10.1007/s11060-004-8093-6 · 2005 · External reference
Central nervous system metastases
10.1016/j.hoc.2021.08.004 · 2022 · External reference
Major features of the 2021 WHO classification of CNS tumors
10.1007/s13311-022-01249-0 · 2022 · External reference
The 2021 World Health Organization classification of tumors of the central nervous system: what neuroradiologists need to know
10.3174/ajnr.a7462 · 2022 · External reference
Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system
10.1002/cncr.33918 · 2022 · External reference
The 2021 WHO classification of tumors of the central nervous system: a summary
10.1093/neuonc/noab106 · 2021 · External reference
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21834 · 2024 · External reference
Cancers of the brain and central nervous system: global patterns and trends in incidence
10.1007/s11060-025-04944-y · 2025 · External reference
Global burden of brain and central nervous system cancer in 185 countries, and projections up to 2050: a population-based systematic analysis of GLOBOCAN 2022 - PubMed
10.1007/s11060-025-05164-0 · 2025 · External reference
Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier
10.4161/mabs.3.2.14239 · 2011 · External reference
The blood–brain barrier and blood–tumour barrier in brain tumours and metastases
10.1038/s41568-019-0205-x · 2019 · External reference
Bridging the blood-brain barrier: strategies to improve delivery of biologics to tumors in the brain
10.1186/s12987-026-00760-2 · 2026 · External reference
Reversing chemokine/chemokine receptor mismatch to enhance the antitumor efficacy of CAR-T cells
10.2217/imt-2021-0228 · 2022 · External reference
Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b
10.1097/cji.0b013e3181ee6675 · 2010 · External reference
Targeting endothelial cell anergy to improve CAR T cell therapy for solid tumors
10.1016/j.bbcan.2024.189155 · 2024 · External reference
Tumor-associated extracellular matrix obstacles for CAR-T cell therapy: approaches to overcoming
10.3390/curroncol32020079 · 2025 · External reference
The role of the extracellular matrix in cancer stemness
10.3389/fcell.2019.00086 · 2019 · External reference
Regression of glioblastoma after chimeric antigen receptor T-cell therapy
10.1056/nejmoa1610497 · 2016 · External reference
Optimization of IL13Rα2-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma
10.1016/j.ymthe.2017.10.002 · 2018 · External reference
Regional delivery of chimeric antigen receptor–engineered T cells effectively targets HER2+ breast cancer metastasis to the brain
10.1158/1078-0432.ccr-17-2041 · 2018 · External reference
Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma
10.1158/1078-0432.ccr-15-0428 · 2015 · External reference
Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis
10.1038/s41591-021-01404-8 · 2021 · External reference
Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors
10.1038/s41591-020-0821-8 · 2020 · External reference
Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma
10.1038/s41591-020-0827-2 · 2020 · External reference
Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma
10.1056/nejmoa2314390 · 2024 · External reference
State of the art in CAR-T cell therapy for solid tumors: is there a sweeter future
10.3390/cells13090725 · 2024 · External reference
Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial
10.1038/s41591-024-02875-1 · 2024 · External reference
IL-13Rα2-targeted CAR T cells show promise in patients with recurrent high-grade gliomas
10.1038/s41571-024-00885-z · 2024 · External reference
Structural insights into the activation and inhibition of CXC chemokine receptor 3
10.1038/s41594-023-01175-5 · 2024 · External reference
CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells
10.1016/j.omto.2021.07.003 · 2021 · External reference
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
10.1182/blood-2009-03-209650 · 2009 · External reference
Chemokine receptors as therapeutic tools in Hodgkin lymphoma: CCR4 and beyond
10.1182/blood-2009-10-247809 · 2010 · External reference
Molecular insights into ligand recognition and activation of chemokine receptors CCR2 and CCR3
10.1038/s41421-022-00403-4 · 2022 · External reference
Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient
10.1186/s40425-016-0125-1 · 2016 · External reference
Tissue-specific role of CX3CR1 expressing immune cells and their relationships with human disease
10.4110/in.2018.18.e5 · 2018 · External reference
Circadian expression of migratory factors establishes lineage-specific signatures that guide the homing of leukocyte subsets to tissues
10.1016/j.immuni.2018.10.007 · 2018 · External reference
Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy
10.1016/j.cell.2024.04.015 · 2024 · External reference
The principles of engineering immune cells to treat cancer
10.1016/j.cell.2017.01.016 · 2017 · External reference
CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors
10.1038/s41467-019-11869-4 · 2019 · External reference
Engineered CXCR3-A expression enhances B7-H3-targeting CAR T cell migration and efficacy against diffuse intrinsic pontine glioma
10.1038/s41467-025-64861-6 · 2025 · External reference
Targeting the tumor vasculature to enhance T cell activity
10.1016/j.coi.2015.01.011 · 2015 · External reference
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy
10.1126/science.1104819 · 2005 · External reference
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases
10.1016/j.ccr.2004.10.011 · 2004 · External reference
Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice
10.1158/0008-5472.can-12-3913 · 2013 · External reference
Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors
10.1038/s41467-023-40850-5 · 2023 · External reference
Targeting the extracellular matrix with Tenascin-C-specific CAR T cells extends survival in preclinical models of glioblastoma
10.1136/jitc-2024-011382 · 2025 · External reference
Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity
10.1158/2326-6066.cir-13-0027 · 2014 · External reference
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
10.1038/nm.3833 · 2015 · External reference
Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model
10.1080/2162402x.2020.1757360 · 2020 · External reference
The tumor immune microenvironment in primary cns neoplasms: a review of current knowledge and therapeutic approaches
10.3390/ijms24032020 · 2023 · External reference
PD-L1 positive astrocytes attenuate inflammatory functions of PD-1 positive microglia in models of autoimmune neuroinflammation
10.1038/s41467-023-40982-8 · 2023 · External reference
Programs, origins and immunomodulatory functions of myeloid cells in glioma
10.1038/s41586-025-08633-8 · 2025 · External reference
CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma
10.1186/s40425-019-0806-7 · 2019 · External reference
Transgenic expression of IL15 improves antiglioma activity of IL13Rα2-CAR T cells but results in antigen loss variants
10.1158/2326-6066.cir-16-0376 · 2017 · External reference
Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment
10.1172/jci.insight.177141 · 2024 · External reference
CAR T-cell therapy for solid tumours
10.1016/s1470-2045(21)00353-3 · 2021 · External reference
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
10.1038/s41591-018-0146-z · 2018 · External reference
Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy
10.1158/2159-8290.cd-15-1020 · 2015 · External reference
Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking
10.1182/blood-2016-05-718395 · 2017 · External reference
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
10.1182/bloodadvances.2022007423 · 2023 · External reference
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia
10.1182/bloodadvances.2021006393 · 2022 · External reference
CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
10.1038/s41586-019-1054-1 · 2019 · External reference
Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy
10.1186/s12943-025-02334-6 · 2025 · External reference
Evolving CAR T-cell therapy to overcome the barriers in treating pediatric central nervous system tumors
10.1158/2159-8290.cd-24-1465 · 2025 · External reference
CAR-T cells immunotherapy in the treatment of glioblastoma
10.1007/s00262-025-04222-w · 2025 · External reference
Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma
10.1093/neuonc/nox182 · 2017 · External reference
Pilot trial of adoptive transfer of chimeric antigen receptor–transduced T Cells targeting EGFRvIII in patients with glioblastoma
10.1097/cji.0000000000000260 · 2019 · External reference
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
10.1126/scitranslmed.aaa0984 · 2017 · External reference
Cytokine release syndrome in solid tumors
10.1002/cncr.70069 · 2025 · External reference
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
10.1038/s41577-021-00547-6 · 2021 · External reference
Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy
10.3389/fimmu.2022.879608 · 2022 · External reference
CAR-T Cells for the treatment of central nervous system tumours: known and emerging neurotoxicities
10.3390/brainsci14121220 · 2024 · External reference
Advances in the mechanisms and management of CAR T-cell toxicities
10.1038/s41571-024-00903-0 · 2024 · External reference
Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating
10.1158/2159-8290.cd-23-0101 · 2023 · External reference
Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy
10.1073/pnas.2312374120 · 2023 · External reference
Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities
10.1007/s00134-024-07576-4 · 2024 · External reference
Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy
10.1182/blood.2025028964 · 2025 · External reference
Pharmacologic control of CAR-T cell function using dasatinib
10.1182/bloodadvances.2018028720 · 2019 · External reference
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
10.1126/scitranslmed.aau5907 · 2019 · External reference
Development of inducible CD19-CAR T cells with a tet-on system for controlled activity and enhanced clinical safety
10.3390/ijms19113455 · 2018 · External reference
An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy
10.1038/mt.2010.83 · 2010 · External reference
Inclusion of the inducible caspase 9 suicide gene in CAR construct increases safety of CAR.CD19 T cell therapy in B-Cell Malignancies
10.3389/fimmu.2021.755639 · 2021 · External reference
The inducible caspase-9 suicide gene system as a safety switch to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells
10.3389/fphar.2014.00235 · 2014 · External reference
Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia
10.1172/jci84813 · 2016 · External reference
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival
10.1093/neuonc/noad002 · 2023 · External reference
Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial
10.1186/2051-1426-3-s2-o11 · 2015 · External reference
Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse
10.1016/j.cell.2026.03.047 · 2026 · External reference
CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome
10.1172/jci150807 · 2022 · External reference
Central nervous system tumours
2021 · External reference
CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2018-2022
10.1093/neuonc/noaf194 · 2025 · External reference
P12.13.B locoregional bi-specific CAR-T cells targeting CD44 and CD133 in recurrent glioblastoma: the first in-human clinical trial results
10.1093/neuonc/noae144.226 · 2024 · External reference
A phase 1 study of B7H3 CAR-T cells aministered intracranially in recurrent glioblastoma
2025 · External reference
Safety and efficacy of B7-H3 targeting CAR-T cell therapy for patients with recurrent GBM
10.1200/jco.2024.42.16_suppl.2062 · 2024 · External reference
Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results
10.1038/s41591-024-02893-z · 2024 · External reference
Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: interim clinical experience demonstrating feasibility and safety
10.1016/j.xcrm.2025.102302 · 2025 · External reference
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial
10.1038/s43018-023-00709-6 · 2024 · External reference
Safety and antitumor activity of GD2-specific 4SCAR-T cells in patients with glioblastoma
10.1186/s12943-022-01711-9 · 2023 · External reference
Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma
10.1080/2162402x.2018.1434464 · 2018 · External reference
Targeting TGFβ docking receptor glycoprotein A repetitions predominant (GARP) via novel chimeric antigen receptor (CAR)-T cell platform to treat glioblastoma
10.1093/neuonc/noaf195 · 2025 · External reference
663MO phase I trial of an IL13Rα2-targeted CAR-T cell therapy for recurrent Malignant glioma: clinical results and pharmacokinetics
10.1016/j.annonc.2025.08.1238 · 2025 · External reference
First-in-human trial of EphA2-redirected CAR Tccells in patients with recurrent glioblastoma: a preliminary report of three cases at the starting dose
10.3389/fonc.2021.694941 · 2021 · External reference
A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL)
10.1200/jco.2024.42.16_suppl.2006 · 2024 · External reference
CTIM-15. Locoregional administration of B7-H3-CAR T cells expressing 41BB ligand for pediatric patients with primary CNS tumors: preliminary results from a phase I study
10.1093/neuonc/noae165.0348 · 2024 · External reference
GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma
10.1158/1078-0432.ccr-23-1880 · 2024 · External reference
Expansion of endogenous T cells in CSF of pediatric CNS tumor patients undergoing locoregional delivery of IL13Ra2-targeting CAR T cells: an interim analysis
10.21203/rs.3.rs-3454977/v1 · 2023 · External reference
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
10.1038/s41586-022-04489-4 · 2022 · External reference
Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial
10.1038/s41591-024-03451-3 · 2025 · External reference
Constitutive signaling from an engineered IL-7 receptor promotes durable tumor elimination by tumor redirected T-cells
10.1158/2159-8290.cd-17-0538 · 2017 · External reference
Phase I trial of GD2.CART cells augmented with constitutive interleukin-7 receptor for treatment of high-grade pediatric CNS tumors
10.1200/jco.23.02019 · 2024 · External reference
Locoregional infusion of EGFR806-CAR T cells for recurrent or refractory pediatric CNS tumors: results of the completed BrainChild02 phase 1 clinical trial
10.1093/neuonc/noaf064 · 2025 · External reference
Targeting cancer leptomeningeal metastasis with allogeneic chimeric antigen receptor γδ T-cell therapy
10.1200/jco.2025.43.16_suppl.2533 · 2025 · External reference
CTIM-07. A phase 1 study of intraventricularly administered autologous her2-targeting chimeric antigen receptor T cells (HER2-CAR T cells), with and without lymphodepletion, in HER2-positive breast cancer patients with recurrent brain and/or leptomeningeal metastases
10.1093/neuonc/noaf201.0464 · 2025 · External reference
